Evaluation of potentiation of anti-PD-L1 treatment using in vitro models

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14160%2F25%3A00141575" target="_blank" >RIV/00216224:14160/25:00141575 - isvavai.cz</a>
Result on the web
<a href="https://fd2025.sk/assets_congress/fd2025_sk2025/docs/72-nd-czech-slovak-pharmacological-days_1.pdf" target="_blank" >https://fd2025.sk/assets_congress/fd2025_sk2025/docs/72-nd-czech-slovak-pharmacological-days_1.pdf</a>
DOI - Digital Object Identifier
—

Result language
angličtina
Original language name
Evaluation of potentiation of anti-PD-L1 treatment using in vitro models
Original language description
Immunotherapy has become one of the most important approaches to cancer treatment. Inhibition of immune system checkpoints, specifically targeting programmed cell death protein and ligand (PD-1, PD-L1), is a key strategy in cancer immunotherapy. Anti-PD-L1 therapy, which blocks the interaction between PD-L1 on tumor cells and PD-1 on T-lymphocytes, can restore immune activity and promote tumor regression. Despite significant clinical success in several cancers, including non-small cell lung cancer, the therapeutic efficacy of anti-PD-L1 therapy remains limited in a subgroup of patients. Therefore, potential strategies to enhance therapeutic response are currently under investigation. Our study focuses on evaluating potentiation of anti-PD-L1 therapy using in vitro models. Namely, two types of co-culture models of activated T-lymphocytes, PD-L1-expressing tumor cell lines and anti-PD-L1 antitumor immunotherapy representative were developed. Their functionality was verified using salicylanilide derivatives. Our co-culture models are of great importance for the study of potentiation of antitumor immunotherapy in vitro.
Czech name
—
Czech description
—

Publication year
2025
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)